Search results
Bristol Myers Squibb's Combo Therapy Shows Sustained Benefits Over Pfizer's Cancer Drug In Kidney...
Benzinga via Yahoo Finance· 3 months agoBristol Myers Squibb & Co (NYSE:BMY) announced that Opdivo (nivolumab) plus Yervoy (ipilimumab)...
Exelixis (EXEL) Cabometyx Combo Study Meets Primary Goal
Zacks via Yahoo Finance· 2 years agoExelixis'(EXEL) late-stage study evaluating the combination of Cabometyx and Opdivo and Yervoy...
Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study
Zacks via Yahoo Finance· 11 months agoBristol Myers (BMY) reports encouraging four-year clinical efficacy results from its lung cancer...
Exelixis (EXEL) Reports Positive Cabometyx Combo Study Results
Zacks via Yahoo Finance· 2 years agoExelixis EXEL has announced detailed results from the ongoing phase III study, COSMIC-313. The...
Bristol Myers' Opdivo-Yervoy combo meets main goal in liver cancer trial
Reuters via Yahoo News· 1 month agoThe treatment, tested in patients with advanced hepatocellular carcinoma (HCC), met the main goal of...
Bristol Myers' Opdivo+Yervoy Fails To Meet Survival Endpoint In Untreated Urothelial Cancer
Benzinga via Yahoo Finance· 2 years agoBristol Myers Squibb & Co's (NYSE: BMY) Phase 3 CheckMate -901 trial of Opdivo (nivolumab) plus...
Biotech Stock Roundup: BMY's Opdivo Updates, Pipeline Updates From REGN, BIIB
Zacks via Yahoo Finance· 2 years agoThe biotech sector has been in the spotlight in the past week, with regular pipeline and regulatory...
Bristol Myers' (BMY) Opdivo Meets Main Goal in Melanoma Study
Zacks via Yahoo Finance· 2 years agoBristol Myers' (BMY) immuno-oncology drug Opdivo demonstrates a statistically significant and...
Bristol Myers' (BMY) Opdivo SC Meets Kidney Cancer Study Goals
Zacks via Yahoo Finance· 6 months agoBristol Myers' (BMY) subcutaneous formulation of Opdivo, developed using Halozyme's Enhanze...
Bristol Myers' (BMY) Opdivo Combos Get FDA Nod for ESCC
Zacks via Yahoo Finance· 2 years agoBristol Myers (BMY) secures an FDA approval for two Opdivo-based regimens as the first-line...